Skip to content

The finder

Pick what you want to change. See who actually measured it.

Every other tool like this gives you a compound and a match score. Those scores are not measured. Ours does not exist. What you get instead is what was actually measured and where: trials in people first with the participant count, then the animal and cell work kept separate, then what people using it report, and the trials that found nothing, counted rather than dropped.

82 of the 444 compounds here have never been through a trial in people. That is worth knowing and it is not a verdict: a molecule nobody can patent has no sponsor to pay for a trial, so a thin human record is usually a fact about money rather than about the compound. Where that is the case, this says so and shows you what does exist.

What are you trying to change?

Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive, so you can see where the evidence is before you choose.

Or start from the compounds

Somebody handed you a stack. What is actually known about it?

Add what you are looking at and you get every outcome those compounds have been measured for in people, and then the longer list of the ones they have not.

Joint and knee pain

Will it help my knees?

One of the two things people most often report trying peptides for, and one of the thinnest human evidence bases on this site.

796 people · 3 human studies · 3 compounds

  1. 01MelittinPeptide
    538 people1 study

    • Whole purified venom, not melittin. 538 patients with knee osteoarthritis randomised 1:2 to histamine control or 100 mcg venom in 15 dermal injections at acupuncture points weekly for 12 weeks. WOMAC pain improved 1.1 points more than control (95% CI 0.3 to 2.0, p = 0.001) and physical function 3.1 points (p =...

      Journal of Alternative and Complementary Medicine, 2019 · 538 people

  2. 02UBX0101Small molecule
    183 people1 study

    • Unity Biotechnology, phase 2, randomised, triple masked, 183 participants (placebo 46, UBX0101 0.5 mg 45, 2.0 mg 46, 4.0 mg 46). Results posted December 2021. WOMAC pain subscale fell from about 2.1 at baseline to 1.12 on placebo versus 1.16, 1.04 and 1.10 on the three doses at week 12. Function and daily pain scores...

      ClinicalTrials.gov, 2026 · 183 people

  3. 03Alpha-2-MacroglobulinBiologic
    75 people1 study1 found nothing

    • found nothingDouble-blinded randomised controlled trial at a single centre, enrolling June 2018 to May 2019. 75 people with symptomatic Kellgren-Lawrence grade 2 or 3 knee osteoarthritis randomised to intra-articular A2M-rich concentrate, conventional platelet-rich plasma, or methylprednisolone, followed 12 weeks; 68 (90.7...

      Bulletin of the Hospital for Joint Diseases, 2024 · 75 people

  4. 04PiperlongumineSmall molecule
    no headcount stated0 studies

    • Rat osteoarthritis model, with supporting experiments in meniscus cells and chondrocytes from patients with osteoarthritis. Piperlongumine reduced p16 and p21 and senescence-associated secretory factors and slowed disease progression in the rats. The human component is cells in a dish, not treated patients.

      Biochemical and Biophysical Research Communications, 2026 · no headcount in the line

  5. 05CartalaxPeptide
    no headcount stated0 studies

    • Cell culture. The senescence-associated secretory phenotype of chondrocytes was characterised by raised p16, p21 and p53, raised TNF-alpha and IL-1-alpha, and lowered Sirt1. Both the AED peptide and a cartilage polypeptide complex normalised the synthesis of those molecules. Chondrocytes in culture, not joints, and no...

      Advances in Gerontology, 2023 · no headcount in the line

  6. 06Nandrolone decanoateHormone
    no headcount stated0 studies
    • 07BPC-157Peptide
      no headcount stated0 studies
      • 08RapamycinSmall molecule
        no headcount stated0 studies
        • 09GLOW blendBlend
          no headcount stated0 studies
          • 10Rapamycin plus acarboseSmall molecule
            no headcount stated0 studies
            • 11Testosterone cypionateHormone
              no headcount stated0 studies
              • 12Deadpool blendBlend
                no headcount stated0 studies
                • 13PDA with TB-500Blend
                  no headcount stated0 studies
                  • 14Semaglutide with BPC-157Blend
                    no headcount stated0 studies

                    How this is counted

                    Human studies only. Animal and test-tube work never enters this ranking, because the question you asked was about a person.

                    A compound is listed for an outcome only when a citation on its own page states that outcome and reports a result for it. Naming it is not enough: a paper that measures testosterone and reports a result about something else does not count as testosterone evidence, which is a mistake this tool made on its first run and no longer makes.

                    People counts are read out of the study lines themselves and are deliberate undercounts. Where a line states no number, the study still counts as a study and adds nothing to the headcount. Counts are never added across compounds, because the same person can appear in more than one trial.

                    Ranking is by people measured. That is a fact about the evidence, not a judgement about the compound, and it is the only ordering this site will defend. A compound at the top of a list is the most studied, which is not the same as the best.

                    Nothing here is advice, and nothing here is a recommendation to take anything.

                    How we grade evidence